A novel phosphodiesterase isozyme target and class of inhibitors for lung cancer
Ended Cooperative Agreement Awarded Last action
- Award ID
- R43CA189613
- Recipient
-
ADT Pharmaceuticals, LLC UEI YL5LNM35E194
- Awarding agency
-
National Institutes of Health
Department of Health and Human Services
- Obligated
- $224,630
Award facts
- Assistance listing
- 93.395 Cancer Treatment Research
- Completion date
- Originally
- Funding agency
- Department of Health and Human Services
- Place of performance
- Daphne, AL 36526, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | -$249 | |
| Original award | $224,879 |
Quick answers
Who received award R43CA189613?
R43CA189613 was awarded to ADT Pharmaceuticals, LLC by National Institutes of Health (Department of Health and Human Services) on June 9, 2015.
How much is award R43CA189613 worth?
$224,630 has been obligated on R43CA189613.
Which agency awarded R43CA189613?
National Institutes of Health (Department of Health and Human Services) awarded R43CA189613, with funding from Department of Health and Human Services.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award